Philip A. Krieter

1.0k total citations
21 papers, 792 citations indexed

About

Philip A. Krieter is a scholar working on Pharmacology, Molecular Biology and Pharmacology. According to data from OpenAlex, Philip A. Krieter has authored 21 papers receiving a total of 792 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pharmacology, 5 papers in Molecular Biology and 5 papers in Pharmacology. Recurrent topics in Philip A. Krieter's work include Pharmacogenetics and Drug Metabolism (5 papers), Pain Mechanisms and Treatments (4 papers) and Drug Transport and Resistance Mechanisms (4 papers). Philip A. Krieter is often cited by papers focused on Pharmacogenetics and Drug Metabolism (5 papers), Pain Mechanisms and Treatments (4 papers) and Drug Transport and Resistance Mechanisms (4 papers). Philip A. Krieter collaborates with scholars based in United States, Poland and Czechia. Philip A. Krieter's co-authors include Phil Skolnick, Mark Gohdes, Timothy J Musick, Rachel Courtney, Monika Martinho, Arnold Lippa, Anthony S. Basile, Piotr Popik, Pál Czobor and C. John Parli and has published in prestigious journals such as Journal of Agricultural and Food Chemistry, Journal of Medicinal Chemistry and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Philip A. Krieter

21 papers receiving 741 citations

Peers

Philip A. Krieter

CMN

PHARM

EPIDE

John P. Gonzalez United Kingdom

J. N. Colin France

H. Friedman United States

Ryan Z. Turncliff United States

Manuel Vaz‐da‐Silva Portugal

Edward J. Randinitis United States

Tadashi Ohkubo Japan

Hisakuni Hashimoto Japan

Michael Skinner United States

Malini Haria New Zealand

John P. Gonzalez United Kingdom

Philip A. Krieter

229 ×1.1

CMN

191 ×1.1

220 ×1.4

PHARM

38 ×0.3

137 ×1.2

EPIDE

Citations per year, relative to Philip A. Krieter Philip A. Krieter (= 1×) peers John P. Gonzalez

Countries citing papers authored by Philip A. Krieter

Since Specialization

Citations

This map shows the geographic impact of Philip A. Krieter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip A. Krieter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip A. Krieter more than expected).

Fields of papers citing papers by Philip A. Krieter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip A. Krieter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip A. Krieter. The network helps show where Philip A. Krieter may publish in the future.

Co-authorship network of co-authors of Philip A. Krieter

This figure shows the co-authorship network connecting the top 25 collaborators of Philip A. Krieter. A scholar is included among the top collaborators of Philip A. Krieter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip A. Krieter. Philip A. Krieter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Krieter, Philip A., et al.. (2019). Fighting Fire with Fire: Development of Intranasal Nalmefene to Treat Synthetic Opioid Overdose. Journal of Pharmacology and Experimental Therapeutics. 371(2). 409–415. 44 indexed citations

Krieter, Philip A., et al.. (2019). Pharmacokinetic Interaction between Naloxone and Naltrexone Following Intranasal Administration to Healthy Subjects. Drug Metabolism and Disposition. 47(7). 690–698. 10 indexed citations

Krieter, Philip A., et al.. (2019). Comparison of the Pharmacokinetic Properties of Naloxone Following the Use of FDA‐Approved Intranasal and Intramuscular Devices Versus a Common Improvised Nasal Naloxone Device. The Journal of Clinical Pharmacology. 59(8). 1078–1084. 22 indexed citations

Krieter, Philip A., et al.. (2019). Enhanced Intranasal Absorption of Naltrexone by Dodecyl Maltopyranoside: Implications for the Treatment of Opioid Overdose. The Journal of Clinical Pharmacology. 59(7). 947–957. 14 indexed citations

Krieter, Philip A., et al.. (2016). Pharmacokinetic Properties and Human Use Characteristics of an FDA‐Approved Intranasal Naloxone Product for the Treatment of Opioid Overdose. The Journal of Clinical Pharmacology. 56(10). 1243–1253. 80 indexed citations

Warnock, Kaitlin T., Jacek Mamczarz, Harry L. June, et al.. (2011). Effects of the Triple Monoamine Uptake Inhibitor DOV 102,677 on Alcohol‐Motivated Responding and Antidepressant Activity in Alcohol‐Preferring (P) Rats. Alcoholism Clinical and Experimental Research. 36(5). 863–873. 7 indexed citations

Musick, Timothy J, et al.. (2007). Pharmacokinetics, Disposition, and Metabolism of Bicifadine in the Mouse, Rat, and Monkey. Drug Metabolism and Disposition. 36(2). 241–251. 12 indexed citations

Krieter, Philip A., Mark Gohdes, Timothy J Musick, Frederick P. Duncanson, & William E. Bridson. (2007). Pharmacokinetics, Disposition, and Metabolism of Bicifadine in Humans. Drug Metabolism and Disposition. 36(2). 252–259. 17 indexed citations

Erickson, David A., et al.. (2007). In Vitro Metabolism of the Analgesic Bicifadine in the Mouse, Rat, Monkey, and Human. Drug Metabolism and Disposition. 35(12). 2232–2241. 12 indexed citations

10.

Tizzano, Joseph P., D. Sloan Stribling, Diego Pérez–Tilve, et al.. (2007). The Triple Uptake Inhibitor (1 R,5 S)-(+)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0] Hexane Hydrochloride (DOV 21947) Reduces Body Weight and Plasma Triglycerides in Rodent Models of Diet-Induced Obesity. Journal of Pharmacology and Experimental Therapeutics. 324(3). 1111–1126. 19 indexed citations

11.

Basile, Anthony S., Aaron Janowsky, Krystyna Gołembiowska, et al.. (2007). Characterization of the Antinociceptive Actions of Bicifadine in Models of Acute, Persistent, and Chronic Pain. Journal of Pharmacology and Experimental Therapeutics. 321(3). 1208–1225. 49 indexed citations

12.

Skolnick, Phil, Philip A. Krieter, Joseph P. Tizzano, et al.. (2006). Preclinical and Clinical Pharmacology of DOV 216,303, a “Triple” Reuptake Inhibitor. CNS Drug Reviews. 12(2). 123–134. 88 indexed citations

13.

Popik, Piotr, Martyna Krawczyk, Gabriel Nowak, et al.. (2006). The Anxioselective Agent 7-(2-Chloropyridin-4-yl)pyrazolo-[1,5-a]-pyrimidin-3-yl](pyridin-2-yl)methanone (DOV 51892) Is More Efficacious Than Diazepam at Enhancing GABA-Gated Currents at α1 Subunit-Containing GABAA Receptors. Journal of Pharmacology and Experimental Therapeutics. 319(3). 1244–1252. 37 indexed citations

14.

Krieter, Philip A., et al.. (2004). Disposition of Posaconazole following Single-Dose Oral Administration in Healthy Subjects. Antimicrobial Agents and Chemotherapy. 48(9). 3543–3551. 158 indexed citations

15.

Beer, Bernard, et al.. (2004). DOV 216,303, a “Triple” Reuptake Inhibitor: Safety, Tolerability, and Pharmacokinetic Profile. The Journal of Clinical Pharmacology. 44(12). 1360–1367. 41 indexed citations

16.

Mushtaq, Mohammad, Philip A. Krieter, Adria Colletti, et al.. (1996). Absorption, Tissue Distribution, Excretion, and Metabolism of ³H- and ¹⁴C-Labeled Emamectin Benzoate in Rats. Journal of Agricultural and Food Chemistry. 44(10). 3342–3349. 8 indexed citations

17.

Weber, Ann E., Mark Steiner, Philip A. Krieter, et al.. (1992). Highly potent, orally active diester macrocyclic human renin inhibitors. Journal of Medicinal Chemistry. 35(21). 3755–3773. 31 indexed citations

18.

Olins, Gillian M., Philip A. Krieter, Angelo J. Trapani, Kerry L. Spear, & Philippe R. Bovy. (1989). Specific inhibitors of endopeptidase 24.11 inhibit the metabolism of atrial natriuretic peptides in vitro and in vivo. Molecular and Cellular Endocrinology. 61(2). 201–208. 62 indexed citations

19.

Krieter, Philip A. & Russell A. Van Dyke. (1983). Cytochrome P-450 and halothane metabolism. Decrease in rat liver microsomal P-450 in vitro. Chemico-Biological Interactions. 44(3). 219–235. 22 indexed citations

20.

Parli, C. John, Philip A. Krieter, & Barbara Schmidt. (1980). Metabolism of 6-chlorotryptophan to 4-chloro-3-hydroxyanthranilic acid: A potent inhibitor of 3-hydroxyanthranilic acid oxidase. Archives of Biochemistry and Biophysics. 203(1). 161–166. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact